カテゴリ： GlobalData, アメリカ, 企業調査

Anavex Life Sciences Corp (AVXL)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Anavex Life Sciences Corp (AVXL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10019
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：57
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer and malignant melanoma. Its pipeline comprises one drug candidate and several compounds in diverse stages of pre-clinical study. Anavex’s lead compound ANAVEX 2-73 is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and potentially other CNS diseases, including rare diseases. Anavex is headquartered in New York, the US.

Anavex Life Sciences Corp (AVXL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12
Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13
Licensing Agreements 14
Anavex Enters Into Licensing Agreement With Life Science Research Israel 14
Equity Offering 15
Anavex Life Sciences Plans to Raise up to USD50 Million in Public Offering of Shares 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 16
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 17
Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 18
Anavex Life Sciences Announces Private Placement Of Units For US$2.6 Million 19
Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For US$0.1 Million 20
Debt Offering 21
Anavex Life Sciences Completes Private Placement Of Debenture For US$10 Million 21
Anavex Life Sciences Corp – Key Competitors 22
Anavex Life Sciences Corp – Key Employees 23
Anavex Life Sciences Corp – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Anavex Life Sciences reports fiscal third quarter 2018 financial results 25
May 10, 2018: Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results 26
Feb 07, 2018: Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results 27
Dec 11, 2017: Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs 28
Aug 07, 2017: Anavex Reports Fiscal Third Quarter 2017 Financial Results 29
May 10, 2017: Anavex Reports Fiscal Second Quarter 2017 Financial Results 31
Feb 07, 2017: Anavex Reports Fiscal First Quarter 2017 Financial Results 32
Corporate Communications 33
Mar 05, 2018: Anavex Life Sciences Announces Management Changes 33
Jul 20, 2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board 34
Jul 20, 2017: Anavex Life Sciences appoints scientific advisory board member 35
May 01, 2017: Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs 36
Feb 13, 2017: Anavex Life Sciences Strengthens Board of Directors 37
Legal and Regulatory 38
Mar 30, 2017: Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit 38
Jan 03, 2017: Anavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit 39
Product News 40
Nov 21, 2017: Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor 40
08/29/2018: Anavex enrols first patient in Phase llb/lll trial of ANAVEX2-73 41
07/20/2017: Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board 42
07/04/2018: Anavex secures approval to start Phase llb/lll trial of ANAVEX 2-73 43
Clinical Trials 44
Jul 25, 2018: Anavex Life Sciences presents new data identifying treatment response biomarkers in Alzheimer’s Disease patients treated with investigational ANAVEX2-73 at 2018 Alzheimer’s Association International Conference 44
Jul 09, 2018: Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX 2-73 for the Treatment of Parkinson’s Disease Dementia 46
Apr 17, 2018: Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX2-73 in Rett Syndrome 47
Mar 07, 2018: Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT) 48
Jan 16, 2018: Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX2-73 Published in The Journal of Clinical Hypertension 49
Nov 04, 2017: Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX2-73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting 50
Oct 30, 2017: Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference 52
Oct 27, 2017: Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017 53
Oct 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX2-73 in Mild-to-Moderate Alzheimer’s Disease Patients 54
May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference 55
Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Anavex Life Sciences Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Anavex Life Sciences Enters into Partnership with Ariana Pharmaceuticals 12
Anavex Enters Into Agreement With Roskamp Institute To Develop ANAVEX PLUS 13
Anavex Enters Into Licensing Agreement With Life Science Research Israel 14
Anavex Life Sciences Plans to Raise up to USD50 Million in Public Offering of Shares 15
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD29 Million 16
Anavex Life Sciences Files Registration Statement for Public Offering of Shares for up to USD100 Million 17
Anavex Life Sciences to Raise USD0.5 Million in Private Placement of Shares and Warrants 18
Anavex Life Sciences Announces Private Placement Of Units For US$2.6 Million 19
Anavex Life Sciences Completes First Tranche Of Private Placement Of Shares For US$0.1 Million 20
Anavex Life Sciences Completes Private Placement Of Debenture For US$10 Million 21
Anavex Life Sciences Corp, Key Competitors 22
Anavex Life Sciences Corp, Key Employees 23
Anavex Life Sciences Corp, Subsidiaries 24

List of Figures
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Anavex Life Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Anavex Life Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Anavex Life Sciences Corp (AVXL)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hammond Power Solutions Inc (HPS.A)：企業の財務・戦略的SWOT分析
    Hammond Power Solutions Inc (HPS.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Mapi Pharma Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Mapi Pharma Ltd (Mapi Pharma) is a clinical stage pharmaceutical company that offers development of active pharmaceutical ingredients and formulations, and life cycle management products. The company’s lead products include Glatiramer Acetate Depot, an injection for the treatment of multiple …
  • Boursorama Sa
    Boursorama Sa - Strategy, SWOT and Corporate Finance Report Summary Boursorama Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • NorthStar Realty Finance Corp：企業のM&A・事業提携・投資動向
    NorthStar Realty Finance Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NorthStar Realty Finance Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Taisho Pharmaceutical Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Taisho Pharmaceutical Co Ltd (Taisho), a subsidiary of Taisho Pharmaceutical Holdings Co Ltd is a pharmaceutical company that develops, manufactures and markets a range of prescription pharmaceutical and self-medication drugs. The company offers products that include lipovitan D, riup, clari …
  • Harvard Stem Cell Institute-製薬・医療分野：企業M&A・提携分析
    Summary Harvard Stem Cell Institute (HSCI), a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, cor …
  • Alzheimer’s Drug Discovery Foundation-製薬・医療分野：企業M&A・提携分析
    Summary Alzheimer's Drug Discovery Foundation (ADDF), formerly Institute for the Study of Aging is a drug discovery foundation that offers funds for drug discovery and development research programs in the field of Alzheimer’s disease, related dementias and cognitive aging. The foundation offers serv …
  • Knoll, Inc.：企業の戦略・SWOT・財務情報
    Knoll, Inc. - Strategy, SWOT and Corporate Finance Report Summary Knoll, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Temasek Holdings (Private) Ltd：企業のM&A・事業提携・投資動向
    Temasek Holdings (Private) Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Temasek Holdings (Private) Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Angel Yeast Co Ltd：企業の戦略・SWOT・財務情報
    Angel Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Angel Yeast Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • BiosanaPharma BV：製薬・医療：M&Aディール及び事業提携情報
    Summary BiosanaPharma BV (Biosana) is a biotechnology company engaged in the development of monoclonal antibody biologicals (mAbs), biosimilars and biobetters. Its pipeline products include BP001: biosimilar of Omalizumab (anti-allergy); BP002: biosimilar of Denosumab (anti-osteoporosis); BOX001: or …
  • EOH Holdings Ltd (EOH)：企業の財務・戦略的SWOT分析
    EOH Holdings Ltd (EOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Halma Plc (HLMA)：医療機器：M&Aディール及び事業提携情報
    Summary Halma Plc (Halma) develops, produces and sells life protection products to enhance personal and public health. The company’s product portfolio comprises fire detection and suppression systems, corrosion monitoring systems, gas detectors, elevator safety products, water treatment systems, aut …
  • Sectra AB (SECT B)：企業の財務・戦略的SWOT分析
    Sectra AB (SECT B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Payton Planar Magnetics Ltd (PAY)：企業の財務・戦略的SWOT分析
    Payton Planar Magnetics Ltd (PAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Cisco Systems Inc (CSCO)：電力：M&Aディール及び事業提携情報
    Summary Cisco Systems Inc (Cisco) designs, manufactures and sells Internet protocol (IP)-based networking systems and other products. The company’s products are blade switches, analytics and automation software, application networking services, interfaces and modules, optical networking, security, s …
  • Dialog Semiconductor plc (DLG)：電力：M&Aディール及び事業提携情報
    Summary Dialog Semiconductor plc (Dialog) is a supplier of motor control ICs for automotive applications. The company’s product portfolio includes integrated power management, AC/DC power conversion, solid state lighting (SSL), Bluetooth low energy, mixed signal integrated circuits (ICs), hand-held …
  • Driver Group Plc (DRV)：企業の財務・戦略的SWOT分析
    Driver Group Plc (DRV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Shoaibi Group-石油・ガス分野：企業M&A・提携分析
    Summary Shoaibi Group (Shoaibi) is a provider of manufacturing, services, product distribution and investment programs. The company offers active venture capital and private equity investments. It offers services such as marketing and technical services, finance and taxation, public relations, admin …
  • NanoViricides Inc (NNVC)：企業の財務・戦略的SWOT分析
    Summary NanoViricides Inc (NanoViricides) is a nano-biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening viral infections. The company offers nanoviricide drug candidates against epidemic influenzas and bir …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆